Absci (NASDAQ:ABSI) Shares Gap Up – What’s Next?

Absci Corporation (NASDAQ:ABSI) gapped up before the market opened on Thursday . The stock had previously closed at $5.30, but opened at $5.74. Absci shares last traded at $5.6410, with a volume of 803,134 shares trading hands.

Absci News Summary

Here are the key news stories impacting Absci this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate for Absci to ($0.84) from ($0.87), indicating a slightly smaller expected loss.
• Positive Sentiment: The firm also lifted its Q3 2026 EPS estimate to ($0.22) from ($0.23), and kept Q4 2026 at ($0.22), showing incremental improvement in near-term forecasts.
• Positive Sentiment: Longer-term estimates were also nudged higher, including FY2028 EPS to $0.11 from $0.10 and FY2029 EPS to $0.09 from $0.08, reinforcing the view that Absci could turn profitable later in the forecast period.
• Neutral Sentiment: HC Wainwright’s Q1 2027, Q2 2027, Q3 2027, and Q4 2027 estimates remain mixed, with profitability still appearing uneven across quarters.
• Neutral Sentiment: Despite the upgrades, the company is still expected to post losses in the near term, so the stock remains sensitive to execution and future pipeline progress.

Wall Street Analysts Forecast Growth

ABSI has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Absci in a research note on Monday, April 20th. Needham & Company LLC reissued a “buy” rating and issued a $7.00 price objective on shares of Absci in a research note on Wednesday, March 25th. Truist Financial upped their target price on Absci from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Finally, Morgan Stanley set a $4.10 price target on Absci in a report on Thursday. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Absci currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.53.

Absci Price Performance

The firm has a market capitalization of $873.82 million, a P/E ratio of -6.74 and a beta of 2.36. The business has a 50 day moving average price of $3.52 and a 200 day moving average price of $3.34.

Absci (NASDAQ:ABSI) last announced its earnings results on Thursday, May 7th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.01. The firm had revenue of $0.22 million during the quarter, compared to the consensus estimate of $1.39 million. Absci had a negative return on equity of 66.32% and a negative net margin of 6,450.76%. As a group, equities analysts expect that Absci Corporation will post -0.82 EPS for the current year.

Insider Activity

In related news, insider Andreas Busch acquired 100,000 shares of the stock in a transaction dated Thursday, March 12th. The shares were acquired at an average price of $2.29 per share, for a total transaction of $229,000.00. Following the completion of the purchase, the insider owned 421,446 shares in the company, valued at approximately $965,111.34. The trade was a 31.11% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.49% of the company’s stock.

Institutional Trading of Absci

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Quarry LP bought a new position in Absci in the third quarter worth $26,000. BNP Paribas Financial Markets boosted its holdings in Absci by 91.2% during the second quarter. BNP Paribas Financial Markets now owns 11,287 shares of the company’s stock valued at $29,000 after purchasing an additional 5,385 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Absci by 45.9% in the 2nd quarter. Legal & General Group Plc now owns 11,690 shares of the company’s stock valued at $30,000 after purchasing an additional 3,678 shares during the period. HB Wealth Management LLC acquired a new position in shares of Absci in the 3rd quarter worth approximately $31,000. Finally, Principal Financial Group Inc. acquired a new position in shares of Absci in the 3rd quarter worth approximately $31,000. 52.05% of the stock is currently owned by institutional investors and hedge funds.

About Absci

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.